Financing channel feed – Endpoints News

Financing channel feed

Following the flow of the biotech industry, Lava heads to Nasdaq with a gamma delta T cell promise

5 years ago

Neuro upstart launches out of RA Capital’s low-profile incubator with Big Pharma vets, clinical drugs and $80M

5 years ago

'Protein printing' AbSci secures $125M crossover as it expands synthetic biology ambitions

5 years ago

In a first for upstart synthetic biology field, Zymergen files for $100M IPO

5 years ago

Step Pharma closes $41M round to take enzyme targeting lead program into early-stage trial for T cell malignancies

5 years ago

Recursion will take its AI platform public in latest IPO filing, while rare heart mutation biotech jumps on SPAC train

5 years ago

Asher Biotherapeutics joins search for a better IL-2 sans the toxicities

5 years ago

Elisabet de los Pinos and her team fuel up for a late-stage quest to deliver a safe eye cancer drug

5 years ago

XyloCor finds new backing to push regenerative heart disease gene therapy deeper into the clinic

5 years ago

The Ides of March bring no misfortune to biotech, as industry logs second-busiest IPO week of 2021

5 years ago

Top biotech investor Peter Kolchinsky tees up a new SPAC — 3 days after a $300M raise for radiopharmaceuticals play

5 years ago

Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM's platform take

5 years ago

Got a revolutionary healthcare company? Bob Nelsen, Jeff Leiden’s SPAC has $500M to take it public

5 years ago

Hunting unicorn status, the co-inventors of the Oxford-AstraZeneca vaccine raise a monster B round

5 years ago

Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders

5 years ago

Takeda, Sarepta double down on a biotech partner's platform to engineer better AAV capsids by mapping out their structure

5 years ago

Taiwan's Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells

5 years ago

Daphne Koller lines up $400M for a global shopping spree to vault forward on AI drug discovery

5 years ago

Next-gen gene editing upstart is grabbing the brass ring with a $150M crossover play to back its bid on a cure for sickle cell disease

5 years ago

Backed by Indian biosim giant Biocon, bispecifics player Bicara debuts with $40M and solid tumors on the radar

5 years ago

ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

5 years ago

Prometheus and Longboard make the leap to Nasdaq with 9-figure offerings and are joined by a Falcon Edge-backed SPAC

5 years ago

BARDA bets $86M on ContraFect's PhIII bid against drug-resistant Staph

5 years ago

Monte Rosa pulls in $95M to test its 'molecular glues,' and the first target is GSPT1

5 years ago

First page Previous page 79 80 818283 84 85 Next page Last page